Clinical trial registry record

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 30, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05953012
Last registry update
December 30, 2025
Status
Completed
Phase
Phase 1
Sponsor
PharmAbcine
Enrollment
17
Countries
South Korea
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NON RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
17
Population
ALL · 50 Years
Duration
2023-07-20 to 2025-12-17
Intervention
PMC-403
Comparator
Not reported
Outcomes measured
Maximum tolerated dose (MTD) — Baseline upto 4 weeks; Adverse events — Baseline upto 5 months; Vital Signs - Pulse Rate (beats/min) — Baseline upto 5 months; Vital Signs - body temperature — Baseline upto 5 months; Vital Signs - systolic/diastolic blood pressure (mmHg) — Baseline upto 5 months; Laboratory tests - Hematology — Baseline upto 5 months; Laboratory tests - Blood chemistry — Baseline upto 5 months; Laboratory tests - Urinalysis — Baseline upto 5 months; Laboratory tests - Blood coagulation — Baseline upto 5 months; Electrocardiogram (ECG) — Baseline upto 5 months; Ophthalmologic examination - Slit lamp examination — Baseline upto 5 months; Ophthalmologic examination - fundus examination — Baseline upto 5 months; Ophthalmologic examination - spectral domain-optical coherence tomography (SD-OCT) — Baseline upto 5 months; Ophthalmologic examination - intraocular pressure (IOP) — Baseline upto 5 months; Change in best corrected visual acuity (BCVA) — Baseline upto 5 months; Change in central retinal thickness (CRT) — Baseline upto 5 months; Presence of intraretinal fluid (IRF) — Baseline upto 5 months; Presence of subretinal fluid (SRF) — Baseline upto 5 months; Presence of sub-RPE fluid — Baseline upto 5 months; Change from baseline in choroidal neovascularization (CNV) lesion size as measured by Fundus Fluorescein Angiography (F…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON